Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters.
BACKGROUND
Prostate cancer is the most common malignancy affecting men and is a major cause of cancer death. There are increasing data on novel tumor markers, such as gelatinase A, which play a key role in tissue invasion and metastasis.


OBJECTIVE
We designed a study to evaluate total gelatinase A content using a simple and applicable Indirect hemagglutination (IHA) test in harmony with gelatinase A activity in serum samples as compared with prostate-specifc antigen (PSA) parameters.


METHODS
In this study, we analysed the circulating form of gelatinase A (MMP-2) in patients suffering from either benign prostate hyperplasia (n=54) or prostate cancer (n=26) versus normal individuals as control (n=26). The gelatinolytic activity was determined by zymography and total MMP-2 content was measured by a novel IHA method. Total PSA and free PSA were quantified using a standard ELISA technique.


RESULTS
Correlation of densitometric analysis of gelatinase A activity and IHA titer is significant at the 0.01 level (P<0.01, rho=0.916). Correlation of PSA and IHA titer is significant at the 0.01 level (P<0.01, rho=0.746). Correlation of free PSA and IHA titer is significant at the 0.01 level (P<0.01, rho=0.749). Borderline of IHA titer in patients with prostate cancer was 512+/-1 tube titer, in benign prostate hyperplasia patients was 128+/-1 tube titer and the titer in normal individuals was 8+/-1 tube titer.


CONCLUSIONS
These results demonstrate that assessment of gelatinase A might be a promising procedure for monitoring and screening patients with prostate cancer.
Khorramizadeh
Mohammad Reza
MR
School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran. khoramza@sina.tums.ac.ir
Aalizadeh
Nastaran
N
Pezeshki
Mohammad
M
Ghahary
Aziz
A
Zeraati
Hojat
H
Berahmeh
Azar
A
Safa
Omid
O
Saadat
Farshid
F
D000230:Adenocarcinoma / Q000097:blood* / Q000201:enzymology*; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D006386:Hemagglutination Tests; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011469:Prostatic Diseases / Q000097:blood / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000097:blood* / Q000201:enzymology*
D017430:Prostate-Specific Antigen; D020778:Matrix Metalloproteinase 2